Japanese researchers have replaced restriction enzymes with polyethylene glycol-coated silver nanoparticles to cut DNA at chosen sites, producing fragments that join up to five times more efficiently than conventional methods allow. The technique lifted final DNA recovery from 14% to 98% and successfully assembled a functional green fluorescent protein gene that expressed in human HeLa cells.

The study, published in Nucleic Acids Research (2026, 54[11], DOI: 10.1093/nar/gkag525), comes from a team led by Professor Hiroshi Abe and Assistant Professor Masahito Inagaki at Nagoya University, working with Professor Natsuhisa Oka at Gifu University. The Japan Science and Technology Agency and the Japan Agency for Medical Research and Development funded the work.

Why sticky ends matter

Standard DNA assembly relies on restriction enzymes to make cuts and T4 DNA ligase to join the fragments. That approach carries two constraints. Restriction enzymes recognize only certain sequences, and they generate relatively short sticky ends — the exposed single-stranded overhangs that let fragments find and bind to one another. Short overhangs reduce joining efficiency, which becomes a bottleneck when researchers build long DNA molecules for gene therapies, vaccine libraries, engineered proteins, or crop genomes.

The Nagoya-led team revisited a chemical reaction first reported between 1990 and 1992, in which silver ions cut DNA carrying a 3'-thiol modification at specific sites. Silver ions proved effective at cleavage but bound nonspecifically and caused precipitation, leaving only about 14% of the DNA recoverable — far too little for practical use.

From ions to nanoparticles

The researchers hypothesized that silver nanoparticles, unlike dissolved ions, could be separated from the reaction mixture by centrifugation. That reasoning held. Initial experiments showed DNA cleavage efficiency of roughly 50% at 70°C and nearly 100% at 95°C within two hours — temperatures that would, however, damage the long DNA molecules the method is meant to serve.

The team then coated the nanoparticles with polyethylene glycol (PEG), a water-soluble polymer, to improve stability and dispersion. The coating changed the math: cleavage efficiency rose from 36% without PEG to 92% with PEG at 37°C over 31 hours. "In the end, we optimized the conditions to a practical level and, under ambient temperatures, achieved PEG-modified cleaving efficiency above 91% at 50°C within just one to two hours," Inagaki, the study's first author, stated.

The nanoparticles delivered a second advantage the researchers did not have to engineer separately. Unwanted DNA fragments stuck to the nanoparticle surfaces while the desired fragments bearing sticky ends remained in solution. This built-in purification step raised DNA recovery from 14% to 98%.

Longer overhangs, faster joins

The method also generates sticky ends that conventional enzymes struggle to produce. The researchers created fragments with 8-base overhangs and joined them with T4 DNA ligase, achieving roughly twice the efficiency of traditional assembly. With an 18-base overhang, joining efficiency reached 44%, compared with 8% for a conventional 4-base overhang — a fivefold advantage.

To confirm the assembled DNA was biologically functional, the team built a fragment encoding green fluorescent protein, introduced it into HeLa cells, and observed GFP expression — evidence that the cuts and joins had preserved reading-frame accuracy.

Where this could lead

Inagaki framed the applications broadly: "We believe this technology will be useful for synthesizing genomic DNA, with many possible applications in areas such as mRNA library establishment for cancer vaccines and gene therapy, as well as the development of artificial protein drugs and genome crops."

For veterinary medicine, those downstream targets are concrete rather than abstract. Large-scale DNA synthesis underpins recombinant vaccine antigens, gene therapy vectors for inherited diseases in companion animals, engineered protein drugs, and genome-edited livestock and crops. Any method that makes long-sequence assembly faster and cheaper could shorten development timelines for those products, though the study itself tested only in vitro assembly and cell culture, not any animal or field application, and the technique carries no regulatory status with FDA CVM, EMA, or USDA — it is a laboratory tool, not an approved product.

The immediate limitation is scale. The published work demonstrates joining two DNA fragments at a time. "We have shown that two DNA fragments can be joined. Now, we need to confirm whether multiple fragments can be joined at the same time — a key step for building genome-scale DNA," Inagaki said.

The group's next experiments will determine whether the nanoparticle chemistry can handle multi-fragment assembly, the step required before the method can compete with existing genome-scale synthesis platforms.